Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

Filippo Pietrantonio, MD
Published: Wednesday, Aug 10, 2016


Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the benefit of a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).  
 
If this nomogram were to be implemented in clinical trial assessment or inclusion criteria will help enroll patients that can be treated effectively and will most benefit from treatment.
  
The nomogram relies on four variable that impact survival; ECOG performance status, primary tumor resection, LDH value, peritoneal disease. These variables are very easy to collect in daily clinical practice, said Pietrantonio.
 
SELECTED
LANGUAGE

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the benefit of a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).  
 
If this nomogram were to be implemented in clinical trial assessment or inclusion criteria will help enroll patients that can be treated effectively and will most benefit from treatment.
  
The nomogram relies on four variable that impact survival; ECOG performance status, primary tumor resection, LDH value, peritoneal disease. These variables are very easy to collect in daily clinical practice, said Pietrantonio.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x